New drug-eluting stents: polymer-free, biodegradable polymers or bioabsorbable scaffolds?

[1]  Salvatore Cassese,et al.  Stents liberadores de rapamicina sin polímero frente a stents liberadores de paclitaxel con polímero: un análisis de datos de pacientes procedentes de ensayos aleatorizados , 2013 .

[2]  F. Alfonso,et al.  Drug-eluting balloons for restenosis after stent implantation , 2013, The Lancet.

[3]  M. Sabaté,et al.  Registro Español de Hemodinámica y Cardiología Intervencionista. XXI Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2011) , 2012 .

[4]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[5]  Fernando Alfonso,et al.  Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis , 2012, Heart.

[6]  J. M. Hernández,et al.  Trombosis muy tardía con nuevos stents farmacoactivos: ¿ha dejado de ser un asunto relevante? , 2012 .

[7]  S. Windecker,et al.  Very late stent thrombosis with newer drug-eluting stents: no longer an issue? , 2012, Revista espanola de cardiologia.

[8]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[9]  K. Hauptmann,et al.  A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions. , 2012, Journal of the American College of Cardiology.

[10]  A. Kastrati,et al.  Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. , 2011, Circulation.

[11]  F. Alfonso,et al.  Second-generation drug-eluting stents. Moving the field forward. , 2011, Journal of the American College of Cardiology.

[12]  F. Schwarz,et al.  Increased Restenosis Rates 12 Months After Coronary Implantation of the Sirolimus‐Eluting YUKON‐Choice Stent Compared to the Paclitaxel‐Eluting TAXUS Stent , 2010, Clinical cardiology.

[13]  G. Dehmer,et al.  Drug-eluting coronary artery stents. , 2009, American family physician.

[14]  A. Kastrati,et al.  Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. , 2009, JACC. Cardiovascular interventions.

[15]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[16]  A. Wieczorek,et al.  Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. , 2008, European heart journal.

[17]  F. Alfonso.  The "vulnerable" stent why so dreadful? , 2008, Journal of the American College of Cardiology.

[18]  Mitchell W. Krucoff,et al.  A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. , 2008, Journal of the American College of Cardiology.

[19]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.